The incidence of dengue fever epidemics has increased dramatically over the last few decades. However, no vaccine or antiviral therapies is available.
Introduction
Dengue is a mosquito-borne viral disease that has become a major public health concern worldwide in recent years. Annually, 100 million cases of dengue fever (DF) and 500,000 cases of dengue hemorrhagic fever (DHF) occur, particularly in tropical Asia, Latin America, and the Caribbean (5, 21) . At present, dengue is endemic in 112 countries around the world (22). However, there is no vaccine or treatment other than vector control and supportive medical care. The development for safe and effective therapeutics is therefore urgently needed.
The etiological agents involved are four serotypes of dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4), which belong to the genus Flavivirus in the family Flaviviridae. Besides dengue virus, many flaviviruses are important human pathogens, including West Nile (WN), yellow fever (YF), Japanese encephalitis (JE), and tick-borne encephalitis (TBE) viruses. The dengue viral genome is a single-stranded, positive-sense RNA of about 11 kb in length, and contains both a 5'-and 3'-untranslated regions. The genomic RNA encodes one single polyprotein that is co-and post-translationally processed by both viral and cellular proteases into three structural proteins, the capsid (C), premembrane (prM), and envelope (E), and seven nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (20).
Infection by dengue virus is initiated by fusion between the viral membrane and the host membrane. The fusion process is mediated by dengue 4 immunoglobin-like domain III (23) (24) (25) 41) . Similar three-domain organization is found in the E proteins of tick-borne encephalitis virus (30) , West Nile virus (14, 27) , and E1 protein of Semliki Forest virus (18). All these envelope proteins represent a distinct class (class II) of viral fusion proteins, that is different from class I fusion proteins represented by gp120/gp41 of HIV and the hemagglutinin of influenza virus (7, 9, 33) . Recent crystal structure of dengue E protein reveals a hydrophobic pocket occupied by a detergent molecule (β-N-octylglucoside, β-OG) lying at a "hinge" region between domain I and II of E protein, which is important for the low-pH-triggered conformational rearrangement required for fusion (24). The available structural data opens up a new avenue for identifying antiviral agents against early steps of dengue virus infection (29) .
Inhibition of enveloped viruses at the stage of viral entry provides a route for therapeutic intervention, as evidenced by the peptidic HIV entry inhibitor T-20 (15, 34) . Other peptides have demonstrated activity against retroviruses in vitro (6, 31) and paramyxoviruses (16, 39, 40) . Hrobowski and co-workers have identified peptide inhibitors of dengue virus and West Nile virus infectivity using a physio-chemical algorithm (11) . Peptidic antivirals, however suffer from poor absorption from the gastrointestinal tract, necessitating intravenous delivery, and high manufacturing cost, making it impractical to treat most vulnerable dengue patients. We therefore explored the development of non-peptidic small molecules to inhibit dengue virus entry. We hypothesized that in silico docking of small molecule libraries against the dengue E protein's hydrophobic pocket could be successfully applied to identify inhibitors of dengue virus entry. This high on November 3, 2017 by guest http://aac.asm.org/ Downloaded from 6
Materials and Methods

Cells and viruses
A549 cells (ATCC, Cat. No. CCL-185) were maintained in Hams F-12 medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in 5% CO 2 . BHK21 cells were maintained in RPMI1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in 5% CO 2 . C6/36, an Aedes albopictus cell line, was maintained in RPMI1640 medium with 10% FBS and 1% penicillin/streptomycin at 28°C in the absence of CO 2 . Dengue viruses used in this study were prepared by inoculating monolayers of C6/36 cells grown in RPMI1640 medium with 5% FBS and 1% penicillin/streptomycin. After incubating at 28°C for 4-5 days, cell culture supernatant was collected after clarification of cell debris, and stored at -80°C.
Docking method
A subset of the Novartis corporate archive was initially selected for this virtual screening experiment. The 3D structures were generated using CORINA (Molecular Networks GmbH, Erlangen, Germany). Protonation expansion for compounds containing atoms with pKa values within the pH range 5-9 was performed with Ionizer (Schrödinger, LLC, Portland, OR, USA). Energy of all structures were finally minimized with Macromodel (Schrödinger, LLC, Portland, OR, USA) according the MMFFs force field (37) . A library of 586,829 structures was thus obtained.
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Dengue virus envelope glycoprotein structure reported by Modis et al (24) was retrieved from Protein Data Bank (PDB entry 1OKE) and prepared according to the protein preparation module available in the Maestro Modeling package (Schrödinger, LLC, Portland, OR, USA). Water molecules were deleted and the protein structure together with its β-OG ligand were energy minimized within an RMSD limit of 0.30 Å.
The Glide docking suite 2.7 (Schrödinger, LLC, Portland, OR, USA) was used to conduct this HTD screening experiment. Centered on the β-OG ligand location, docking grids were generated according to default parameters. Van der Waals radii scaling factor of non-polar atoms of the protein was set to 0.8. Such value decreases penalties for close contacts and is often used to artificially simulate the flexibility of a binding site. Default docking parameters were applied and all docking calculations were distributed over a linux cluster.
Based on Glide docking score, top 10,000 docking hits were initially selected for further analysis. A 3D pharmacophore was applied to filter out docking poses using Unity program (Tripos, Inc., St. Louis, MO, USA). This pharmacophore contains two donor spheres (located in front of the backbone carbonyl of residue Ala50 and Thr48), one acceptor sphere (located in front of the backbone NH of residue Ala50) and one hydrophobic sphere (located at the 
Compound synthesis
Lead compounds 1-4 were synthesized using procedures previously described 
Time-of-addition study
Two kinds of time-of-addition studies were performed. A549 cells preparation, infection, and viral antigen quantification were performed as described in "CFI assay". In one experiment, serial dilutions of either compound 6 or a control compound were added during and/or after infection. In the other experiment, test
compounds were added at a final concentration of 2µM (compound 6) or 50 µM 
Evaluation of endosomal compartments pH
Coverslips and A549 cells preparation were preformed as described in 
Compound virus binding assay
Micro Biospin 6 column (Bio-Rad) was used to study the binding of compound 6 and 7 to dengue virus particles. Dengue virus (~6x10 7 PFU) was incubated with 5 µM compound 6 or 7 at room temperature for 30 or 5 min, respectively, the virus/compound mixture was then loaded onto the column. After centrifugation, the eluent was used for further analysis. The compound 6/virus eluent was analyzed on a LC/MS/MS system consisting of a 4000 QTrap® triple quadrupole/linear ion trap (QqQLIT) mass spectrometer equipped with a TurboIonSprayTM interface and Agilent 1100 HPLC system with a UV detector. Considering the tertiary structure of the protein in the area of the β-OG binding site and conformational differences with the X-ray structure of the apo form also reported by the same research group, one can suspect that this binding site should be relatively flexible and adapt its shape to the docked ligand. Since one main drawback of current HTD methods is that protein receptor is considered rigid during the docking process, we have used soft Van der Waals contacts parameters to artificially take into account the binding site flexibility.
While HTD virtual screening experiment has been carried out without any were selected for biological testing in a cell-based assay.
Antiviral activities of docking hits and the identification of compound 6
The 111 compounds were next assessed in the cell-based flavivirus (Table 1) were identified from the testing.
The effective concentrations of compound reducing 50% virus antigen production, EC 50 , were calculated to be 1.69 µM and 0.90 µM, respectively. And no cytotoxicity was detected at 20 µM.
By using Compound 1 and 2 as a starting point, detail analysis of structure activity relationship (SAR) was undertaken in an attempt to increase the potency of this class of compound against dengue virus. We identified that both amine R1 as well as the aryl group R2 were necessary for the antiviral activity. Several substitutions were tolerated on aryl ring R2, with 4-halo substituent being the optimum (3, Table 1 ). Both primary and secondary, as well as both aryl and alkyl amines showed potency, but piperazine was one of the most potent amines (4, on November 3, 2017 by guest http://aac.asm.org/ Downloaded from Table 1 ). Changing the pyrimidine ring to quinazoline ring was very fruitful further improving the potency (5 and 6, Table 1 ). Treatment of A549 cells with compound 6 reduced virus growth and antigen production in a dose dependent manner ( Figure 1 A and B) . Virus production was completely inhibited at a concentration of 2.5 µM or above ( Figure 1A ). The spectrum of activity of compound 6 against four serotypes of dengue virus was examined by using the CFI assay. Compound 6 was efficacious against all serotypes, both laboratory strains and clinical isolates, with EC 50 s ranging from 0.068 to 0.496 µM ( Table 2 ).
The average EC 50 for the 4 viral strains was 0.252 µM. In addition, compound 6
was efficacious against other flaviviruses, including YFV, WNV, and JEV (Table   2 ).
Compound 6 acts at early stage during dengue virus infection
To determine the antiviral target of compound 6, time-of-addition experiments using the CFI assay were performed. Serial dilutions of compound 6 or the control compound (7-deaza-2'-C-methyl-adenosine) (28) were added during and/or after 1 h infection. As shown in Figure 2A , compound 6 had similar EC 50 s whether added only during the virus infection period or throughout the entire assay. But it was about 100-fold less active when added only after virus infection.
Conversely, the control compound, which inhibits dengue NS5 polymerase at a 
Compound 6 binds with dengue virus particles
We next wished to address the question of whether the target of compound 6 is the virus, a Micro BioSpin 6 column gel filtration method was used with modification (8). When compound 6 was incubated with dengue virus particles and loaded onto a spin column, it eluted from the column upon centrifugation. In contrast, in the absence of virus, compound 6 was not detected in the elution fraction analyzed by LC-MS ( Figure 4A ). Additionally, when an inactive compound (EC 50 >20 µM) with similar lipophilicity was incubated with virus, there was background level of the compound eluted. It suggests that the binding of compound 6 with dengue virus is most likely specific.
To confirm the binding of compound 6 with virus particles, a biotinylated compound 7 (EC 50 =0.234 µM, Figure 4B ), was synthesized to analyze its co- Figure   4C , at 2h post infection, most of the E protein signal co-localized with compound 7 in the cytoplasm in punctuated structures.
Docking pose of compound 6 with dengue E protein
In the absence of a co-crystal containing compound 6 and dengue E protein, GOLD docking (13) In the time-of-addition experiments, it clearly shows that compound 6
interacts with an early event in the dengue virus life cycle, which was defined as the entry step. As virus entry is a multi-step process, the data from immunofluorescence studies further pinpoint that compound 6 blocks dengue virus entry after the virus internalized into endosomes. We speculate that the on November 3, 2017 by guest http://aac.asm.org/ Downloaded from compound interacts with the viral-endosomal membrane fusion step. Since the fusion step is mainly driven by E protein in response to low pH, and there is no observed adverse effect of compound 6 on the acidification of endosomes, it is reasoned that E protein is the presumable target.
This hypothesis is further supported by a direct virus-compound binding assay, where compound 6 co-eluted with virus particles from a gel filtration spin column. The results of co-localization of a biotinylated compound 7 with virus during infection are also consistent with an interaction between the compound and the E protein.
Compound 6 can be readily modeled into the hydrophobic pocket with GOLD in an orientation where the chloro-phenyl-thiophene tail is well-buried, and the rest of molecule being solvent-exposed. Apo crystal structures of the DENV-3 and WNV E protein, in the "closed" form, have been published recently (14, 25, 27) . As the hydrophobic channel is only present in the "open" form, it is impossible to obtain a direct comparison of the β-OG binding site between DENV-2, DENV-3 and WNV. However, given the very high sequence identity between DENV-2 and DENV-3 (68%), it is reasonable to expect that compound 6 might also inhibit DENV-3, which is inline with our experimental result ( Table 2) .
On the other hand, the sequence identity between DENV-2/DENV-3 and WNV is somewhat lower (~40%). Unlike DENV-2/DENV-3 which crystallize as dimers,
the WNV E protein crystallizes as a monomer. Interestingly, it has also been reported that WNV E protein fails to crystallize in the presence of β-OG despite repeated attempts (27) . All these suggest that compound 6 may behave on November 3, 2017 by guest http://aac.asm.org/ Downloaded from differently in WNV, which explains why the compound is relatively less active against this virus (Table 2) .
Taken together, our data strongly suggest that compound 6 interacts with the E protein therefore blocking the virus entry process. The precise mode of action remains to be characterized. Generation of compound 6-resistant dengue virus variants will be one of the ways to identify the target. 
